| 嵌合抗原受体T细胞免疫疗法在B细胞非霍奇金淋巴瘤中的研究进展 |
| |
| 引用本文： | 赵培起,张会来. 嵌合抗原受体T细胞免疫疗法在B细胞非霍奇金淋巴瘤中的研究进展[J]. 天津医药, 2020, 48(1): 71-75. DOI: 10.11958/20191721 |
| |
| 作者姓名： | 赵培起 张会来 |
| |
| 作者单位： | 基金项目：国家自然科学基金资助项目（81402575）作者单位：天津医科大学肿瘤医院淋巴瘤内科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津市恶性肿瘤临床医学研究中心（邮编300060）作者简介：赵培起（1985）,男,博士,主治医师,讲师,主要从事淋巴瘤的个体化诊断及治疗△通讯作者 E-mail: zhlwgq@126.com |
| |
| 基金项目： | 高效智能核壳纳米递送系统介导survivin siRNA和阿霉素逆转乳腺癌多药耐药的机制研究 |
| |
| 摘 要： | 摘要：非霍奇金淋巴瘤（NHL）是最常见的血液系统恶性肿瘤,复发难治患者预后欠佳。嵌合抗原受体T细胞免疫疗法（CAR-T）是近年来新兴的免疫治疗方法,在恶性肿瘤尤其是血液系统恶性肿瘤治疗方面取得了较多突破,尤其是给复发难治的B细胞NHL患者带来了希望。目前,美国食品药品监督管理局（FDA）已批准两款CAR-T细胞疗法tisagenlecleucel和axicabtagene ciloleucel,其他几种产品仍在临床试验中。本文就CAR-T的结构及其在常见B细胞NHL中的疗效、安全性及研究趋势做一综述。
|
| 关 键 词： | 淋巴瘤 免疫疗法 综述 嵌合抗原受体T细胞 |
| 收稿时间： | 2019-06-10 |
| 修稿时间： | 2019-08-11 |
Research progress of chimeric antigen receptor T cell immunotherapy inB-cell non-Hodgkin lymphoma |
| |
| ZHAO Pei-qi,ZHANG Hui-lai. Research progress of chimeric antigen receptor T cell immunotherapy inB-cell non-Hodgkin lymphoma[J]. Tianjin Medical Journal, 2020, 48(1): 71-75. DOI: 10.11958/20191721 |
| |
| Authors: | ZHAO Pei-qi ZHANG Hui-lai |
| |
| Affiliation: | Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center forCancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’sClinical Research Center for Cancer, Tianjin 300060, China△Corresponding Author E-mail: zhlwgq@126.com |
| |
| Abstract: | Abstract: Non-Hodgkin lymphoma (NHL) is the most common hematological malignancy, and the prognosis of patientswith relapse and refractory is poor. Chimeric antigen receptor T-cell immunotherapy (CAR-T) is a new immunotherapymethod in recent years, which has made many breakthroughs in the treatment of malignant tumors, especially hematologicaltumors. In particular, there is hope for patients with relapsed and refractory B-cell NHL. At present, Food and DrugAdministration (FDA) has approved two CAR-T cell therapy tisagenlecleucel and axicabtagene ciloleucel. Several otherproducts are still in clinical trials. This article reviews the structure of CAR-T and its efficacy, safety and research trends incommon B-cell NHL |
| |
| Keywords: | lymphoma immunotherapy review chimeric antigen receptor T cell |
|
| 点击此处可从《天津医药》浏览原始摘要信息 |
|
点击此处可从《天津医药》下载免费的PDF全文 |
|
